Sumitomo Pharma Co. Ltd (SMDPY PINK) stock market data APIs
$9.2574
0(0%)
as of July 3, 2026
Try our APIs with
free plan!
Sumitomo Pharma Co. Ltd Financial Data Overview
Price chart is built with
Anychart
Sumitomo Pharma Co., Ltd. Manufactures, purchases, and sells pharmaceutical products for medical treatment in Japan, North America, and Asia. It offers therapeutic agents for parkinson's disease, type 2 diabetes, uterine fibroids and endometriosis, overactive bladder, and pediatric congenital athymia. The company also provides atypical antipsychotic, generic products, antiepileptic, atypical antipsychotic, and carbapenem antibiotic. In addition, it offers veterinary medicines, medical devices, etc. The company has collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was formerly known as Sumitomo Dainippon Pharma Co., Ltd. and changed its name to Sumitomo Pharma Co., Ltd. in April 2022. The company was incorporated in 1897 and is headquartered in Osaka, Japan. Sumitomo Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.
Prev. Close
9.2574
Open
9.2574
High
9.2574
Low
9.2574
52 wk Range
6.73-24.48
Market Cap
4 149 M
P/E Ratio
5.5723
Shares Outstanding
449 M
Revenue
453 294 M
EPS
-0.013
Beta
0.478
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Sumitomo Pharma Co. Ltd data using free add-ons & libraries
Get Sumitomo Pharma Co. Ltd Fundamental Data
Sumitomo Pharma Co. Ltd Fundamental data includes:
- Net Revenue: 453 294 M
- EBITDA: 71 929 M
- Earnings Per Share: 1
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-03-31
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Sumitomo Pharma Co. Ltd News
New
Sumitomo Pharma America Announces Encouraging Clinical and Translational Data at EHA 2026, Highlighting Investigational Combination Therapy in Relapsed/Refractory Myelofibrosis and New Research Findings in Menin Inhibition in Leukemia
– Preliminary clinical data on nuvisertib and momelotinib combination highlight encouraging clinical responses with 60% of evaluable patients achieving responses in spleen size, symptoms, and anemia...
Sumitomo Pharma America Achieves Key Patient Enrollment Milestone for Pivotal Phase 2 Study of Enzomenib in the Treatment of Relapsed/Refractory Acute Leukemia
The phase 2 monotherapy study of enzomenib (DSP-5336) in the treatment of relapsed/refractory acute leukemia with KMT2A rearrangement has enrolled the required number of patients for interim analysis ...
Generalized Anxiety Disorder Market Forecast Shows Strong CAGR During the Forecast Period (2026-2036) Driven by Innovative Therapies | DelveInsight
The generalized anxiety disorder market across the 7MM is expected to grow significantly during the forecast period (2026-2036). Key drivers include the increasing prevalence of the disease, advanceme...
Sumitomo Pharma America Presents First Clinical Data for SMP-3124LP, an Investigational PEGylated Liposome CHK1 Inhibitor, at ASCO 2026
First-in-human preliminary results showed SMP-3124LP was generally well-tolerated with manageable safety profile in patients with heavily pretreated advanced solid tumors Early signals of clinical ac...
Get Sumitomo Pharma Co. Ltd fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
